Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:EXEL
- CUSIP: 30161Q10
- Web: www.exelixis.com
Capitalization:- Market Cap: $8.20582 billion
- Outstanding Shares: 293,904,000
Average Prices:- 50 Day Moving Avg: $27.08
- 200 Day Moving Avg: $23.49
- 52 Week Range: $10.04 - $29.50
P/E:- Trailing P/E Ratio: 142.78
- Foreward P/E Ratio: 44.87
- P/E Growth: 2.19
Sales & Book Value:- Annual Revenue: $319.67 million
- Price / Sales: 25.99
- Book Value: $0.51 per share
- Price / Book: 55.43
Profitability:- EBIDTA: $95.32 million
- Net Margins: 18.20%
- Return on Equity: 80.43%
- Return on Assets: 13.93%
Debt:- Current Ratio: 4.12%
- Quick Ratio: 4.06%
Misc:- Average Volume: 4.17 million shs.
- Beta: 1.97
- Short Ratio: 4.61
Frequently Asked Questions for Exelixis (NASDAQ:EXEL)
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.02. The company earned $99.01 million during the quarter, compared to analysts' expectations of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. Exelixis's revenue was up 173.1% on a year-over-year basis. During the same period last year, the company posted ($0.15) EPS. View Exelixis' Earnings History.
When will Exelixis make its next earnings announcement?
Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?
12 analysts have issued 12 month price objectives for Exelixis' shares. Their predictions range from $15.00 to $33.00. On average, they anticipate Exelixis' stock price to reach $26.20 in the next twelve months. View Analyst Ratings for Exelixis.
What are analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
- 1. Cann analysts commented, "Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of Cotellic (cobimetinib). As part of the settlement, effective July 1, 2017, the companies have amended the existing Collaboration Agreement to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016." (7/20/2017)
- 2. According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. The sequential increase in Cabometyx sales is also a positive. Moreover, Cabometyx was also approved in the EU. Meanwhile, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. A potential label expansion will further boost sales. Exelixis also has collaborations with Bristol-Myers and Roche on the development of cabozantinib in combination with immunotherapy agents. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date. However, the company is heavily dependent on Cabometyx for growth now. Operating expenses are also projected to increase." (7/11/2017)
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Kite Pharma (KITE), TESARO (TSRO), BIOVERATIV INC (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), AveXis (AVXS), Sarepta Therapeutics (SRPT), Axovant Sciences Ltd (AXON), GW Pharmaceuticals PLC (GWPH), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Intercept Pharmaceuticals (ICPT) and Loxo Oncology (LOXO).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
- Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
- Christopher J. Senner, Chief Financial Officer, Executive Vice President
- Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
- Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
- Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
- Patrick Haley, Senior Vice President - Commercial
- Charles M. Cohen Ph.D., Independent Director
- Carl B. Feldbaum Esq., Independent Director
- Alan M. Garber M.D. Ph.D., Independent Director
Who owns Exelixis stock?
Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.89%), Vanguard Group Inc. (8.66%), Meditor Group Ltd (6.92%), BlackRock Inc. (5.16%), Matrix Capital Management Company LP (5.14%) and Goldman Sachs Group Inc. (2.40%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Who sold Exelixis stock? Who is selling Exelixis stock?
Exelixis' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Farallon Capital Management LLC, Northern Trust Corp, Teachers Advisors LLC, State Street Corp, Acadian Asset Management LLC, Voya Investment Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Who bought Exelixis stock? Who is buying Exelixis stock?
Exelixis' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Matrix Capital Management Company LP, Janus Henderson Group PLC, Meditor Group Ltd, Renaissance Technologies LLC, FMR LLC, Goldman Sachs Group Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Exelixis.
How do I buy Exelixis stock?
Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of Exelixis stock can currently be purchased for approximately $28.27.
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.58) |
| Consensus Price Target: | $26.20 (7.34% downside) |
Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | Royal Bank Of Canada | Initiated Coverage | Outperform -> Outperform | $32.00 | Medium |  |
| 9/12/2017 | Needham & Company LLC | Reiterated Rating | Buy -> Buy | $28.00 -> $30.00 | Medium | |
| 9/10/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | Medium | |
| 9/10/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $29.00 | Medium | |
| 9/7/2017 | Stifel Nicolaus | Reiterated Rating | Hold | $26.00 | Low | |
| 8/10/2017 | Cowen and Company | Reiterated Rating | Outperform | | Medium | |
| 8/3/2017 | Deutsche Bank AG | Downgrade | Buy -> Hold | $26.00 -> $29.00 | Medium | |
| 7/27/2017 | William Blair | Reiterated Rating | Outperform | | Medium | |
| 7/20/2017 | Cann | Reiterated Rating | Hold | | Low | |
| 7/13/2017 | SunTrust Banks, Inc. | Initiated Coverage | Buy -> Buy | $33.00 | Medium | |
| 3/16/2017 | CIBC | Initiated Coverage | Market Perform -> Market Perform | | High | |
| 10/7/2016 | Leerink Swann | Reiterated Rating | Positive | $15.00 | N/A | |
| 9/28/2016 | S&P Equity Research | Boost Price Target | | $13.41 -> $15.57 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Exelixis (NASDAQ:EXEL)Earnings History by Quarter for Exelixis (NASDAQ EXEL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | $0.05 | | | | | N/A | |
| 8/2/2017 | Q2 2017 | $0.04 | $0.06 | $85.27 million | $99.01 million | View | Listen | |
| 5/1/2017 | Q1 2017 | ($0.01) | $0.05 | $65.23 million | $80.90 million | View | Listen | |
| 2/27/2017 | Q416 | ($0.01) | $0.12 | $64.88 million | $77.58 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.13) | ($0.04) | $43.15 million | $62.19 million | View | N/A | |
| 8/3/2016 | Q216 | ($0.27) | ($0.16) | $16.76 million | $36.25 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.25) | ($0.27) | $9.11 million | $15.40 million | View | Listen | |
| 2/29/2016 | Q415 | ($0.22) | ($0.19) | $8.16 million | $9.94 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.20) | ($0.22) | $9.08 million | $9.85 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.21) | ($0.22) | $8.69 million | $8.00 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.24) | ($0.18) | $8.08 million | $9.40 million | View | Listen | |
| 2/24/2015 | Q414 | ($0.31) | ($0.30) | $7.50 million | $7.35 million | View | Listen | |
| 11/4/2014 | Q314 | ($0.37) | ($0.32) | $6.77 million | $6.30 million | View | Listen | |
| 7/31/2014 | Q214 | ($0.39) | ($0.38) | $5.66 million | $6.56 million | View | Listen | |
| 5/1/2014 | Q114 | ($0.37) | ($0.39) | $6.11 million | $4.90 million | View | Listen | |
| 2/20/2014 | Q413 | ($0.38) | ($0.38) | $5.71 million | $4.34 million | View | Listen | |
| 10/30/2013 | Q313 | ($0.37) | ($0.36) | $5.55 million | $5.50 million | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.30) | ($0.34) | $6.55 million | $11.90 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.29) | ($0.24) | $5.33 million | $9.70 million | View | Listen | |
| 2/21/2013 | Q4 2012 | ($0.24) | ($0.28) | $9.46 million | $7.80 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.30) | ($0.20) | $9.22 million | $13.30 million | View | N/A | |
| 8/2/2012 | | ($0.27) | ($0.25) | | | View | N/A | |
| 5/3/2012 | | ($0.19) | ($0.18) | | | View | N/A | |
| 10/27/2011 | | $0.57 | $0.60 | | | View | N/A | |
| 8/4/2011 | | ($0.17) | ($0.16) | | | View | N/A | |
| 5/3/2011 | | ($0.19) | ($0.24) | | | View | N/A | |
| 2/22/2011 | | ($0.21) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Exelixis (NASDAQ:EXEL)2017 EPS Consensus Estimate: $0.12
2018 EPS Consensus Estimate: $0.54
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.03) | $0.01 | ($0.01) |
| Q2 2017 | 4 | $0.01 | $0.03 | $0.02 |
| Q3 2017 | 4 | $0.05 | $0.07 | $0.06 |
| Q4 2017 | 4 | $0.04 | $0.07 | $0.06 |
| Q1 2018 | 1 | $0.09 | $0.09 | $0.09 |
| Q2 2018 | 1 | $0.10 | $0.10 | $0.10 |
| Q3 2018 | 1 | $0.15 | $0.15 | $0.15 |
| Q4 2018 | 1 | $0.20 | $0.20 | $0.20 |
(Data provided by Zacks Investment Research)
Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 79.20%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/19/2017 | Stelios Papadopoulos | Director | Sell | 200,000 | $27.68 | $5,536,000.00 | |
| 9/18/2017 | Stelios Papadopoulos | Director | Sell | 72,210 | $27.76 | $2,004,549.60 | |
| 9/14/2017 | Michael Morrissey | Insider | Sell | 300,000 | $26.90 | $8,070,000.00 | |
| 9/14/2017 | Patrick J. Haley | VP | Sell | 60,640 | $27.21 | $1,650,014.40 | |
| 9/13/2017 | Lance Willsey | Director | Sell | 100,000 | $26.88 | $2,688,000.00 | |
| 9/12/2017 | Christopher J. Senner | CFO | Sell | 100,000 | $26.79 | $2,679,000.00 | |
| 5/30/2017 | Patrick J. Haley | Insider | Sell | 5,000 | $18.46 | $92,300.00 | |
| 5/15/2017 | Carl B Feldbaum | Director | Sell | 32,988 | $21.58 | $711,881.04 | |
| 5/10/2017 | Michael Morrissey | Insider | Sell | 211,300 | $21.87 | $4,621,131.00 | |
| 5/9/2017 | Michael Morrissey | CEO | Sell | 100,000 | $21.69 | $2,169,000.00 | |
| 5/8/2017 | Michael Morrissey | CEO | Sell | 11,300 | $21.81 | $246,453.00 | |
| 5/5/2017 | Michael Morrissey | Insider | Sell | 259,149 | $22.24 | $5,763,473.76 | |
| 5/1/2017 | Gisela Schwab | CMO | Sell | 89,910 | $23.01 | $2,068,829.10 | |
| 4/3/2017 | Vincent T Marchesi | Director | Sell | 10,000 | $21.30 | $213,000.00 | |
| 3/31/2017 | Jack L Wyszomierski | Director | Sell | 5,150 | $21.57 | $111,085.50 | |
| 3/27/2017 | Jeffrey Hessekiel | EVP | Sell | 6,884 | $21.02 | $144,701.68 | |
| 3/22/2017 | Jeffrey Hessekiel | EVP | Sell | 23,787 | $20.54 | $488,584.98 | |
| 3/20/2017 | Stelios Papadopoulos | Director | Sell | 10,000 | $21.66 | $216,600.00 | |
| 3/13/2017 | Charles Cohen | Director | Sell | 10,000 | $21.82 | $218,200.00 | |
| 3/10/2017 | Vincent T Marchesi | Director | Sell | 40,000 | $21.98 | $879,200.00 | |
| 3/6/2017 | Michael Morrissey | Insider | Sell | 200,000 | $22.72 | $4,544,000.00 | |
| 3/3/2017 | Christopher J. Senner | CFO | Sell | 11,000 | $22.80 | $250,800.00 | |
| 3/2/2017 | George Poste | Director | Sell | 76,250 | $22.53 | $1,717,912.50 | |
| 1/3/2017 | Peter Lamb | EVP | Sell | 70,000 | $14.65 | $1,025,500.00 | |
| 12/16/2016 | Carl B. Feldbaum | Director | Sell | 25,000 | $17.03 | $425,750.00 | |
| 12/9/2016 | Alan M. Garber | Director | Sell | 7,832 | $16.90 | $132,360.80 | |
| 12/7/2016 | George A. Scangos | Director | Sell | 204,894 | $17.81 | $3,649,162.14 | |
| 12/5/2016 | George A. Scangos | Director | Sell | 204,718 | $17.81 | $3,646,027.58 | |
| 12/1/2016 | Gisela Schwab | Insider | Sell | 22,000 | $16.73 | $368,060.00 | |
| 12/1/2016 | Peter Lamb | EVP | Sell | 70,000 | $16.66 | $1,166,200.00 | |
| 8/4/2016 | Gisela Schwab | Insider | Sell | 42,338 | $11.00 | $465,718.00 | |
| 5/11/2016 | Lance Willsey | Director | Buy | 60,000 | $4.97 | $298,200.00 | |
| 5/9/2016 | Lance Willsey | Director | Buy | 40,000 | $4.97 | $198,800.00 | |
| 12/11/2015 | Lance Willsey | Director | Buy | 100,000 | $4.89 | $489,000.00 | |
| 10/16/2015 | Peter Lamb | EVP | Sell | 51,549 | $5.80 | $298,984.20 | |
| 10/13/2015 | Peter Lamb | EVP | Sell | 600 | $5.80 | $3,480.00 | |
| 10/12/2015 | Peter Lamb | EVP | Sell | 300,276 | $5.84 | $1,753,611.84 | |
| 9/17/2014 | Vincent T Marchesi | Director | Buy | 20,000 | $1.71 | $34,200.00 | |
| 8/29/2013 | Lance Willsey | Director | Buy | 10,000 | $5.15 | $51,500.00 | |
| 12/20/2012 | Vincent T Marchesi | Director | Buy | 4,000 | $4.68 | $18,720.00 | |
| 12/19/2012 | Vincent T Marchesi | Director | Buy | 6,000 | $4.72 | $28,320.00 | |
| 12/10/2012 | Gisela Schwab | EVP | Buy | 25,000 | $4.39 | $109,750.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
| Source: |
|
| Date | Headline |
|---|
 | Stelios Papadopoulos Sells 200,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 20 at 7:36 PM |
| Exelixis, Inc. (EXEL) Director Sells $2,004,549.60 in Stock
www.americanbankingnews.com - September 20 at 7:34 PM |
| Exelixis, Inc. (EXEL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 20 at 9:24 AM |
 | Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25 - Business Wire (press release)
www.businesswire.com - September 20 at 4:38 AM |
 | Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25
finance.yahoo.com - September 19 at 6:32 PM |
 | U.S. FDA Grants Fast Track Designation To Pluristem's PLX-PAD For The Treatment Of Critical Limb Ischemia (CLI)
www.thestreet.com - September 18 at 6:19 PM |
 | Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $8.1 million of Shares
www.nasdaq.com - September 16 at 12:03 AM |
| Patrick J. Haley Sells 60,640 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 15 at 7:24 PM |
 | Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
www.fool.com - September 15 at 6:43 AM |
| Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : September 15, 2017
finance.yahoo.com - September 15 at 12:15 AM |
| Michael Morrissey Sells 300,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 14 at 10:35 PM |
| Insider Selling: Exelixis, Inc. (EXEL) Director Sells 100,000 Shares of Stock
www.americanbankingnews.com - September 14 at 10:34 PM |
| Christopher J. Senner Sells 100,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 14 at 10:32 PM |
| Exelixis, Inc. (EXEL) Earns Outperform Rating from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM |
| Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
www.fool.com - September 14 at 3:45 PM |
| Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : September 13, 2017
finance.yahoo.com - September 13 at 7:52 PM |
| FY2018 EPS Estimates for Exelixis, Inc. (EXEL) Increased by Analyst
www.americanbankingnews.com - September 13 at 1:22 PM |
| William Blair Analysts Raise Earnings Estimates for Exelixis, Inc. (EXEL)
www.americanbankingnews.com - September 12 at 4:50 PM |
| Exelixis, Inc. (EXEL) Price Target Raised to $30.00
www.americanbankingnews.com - September 12 at 9:32 AM |
| Exelixis, Inc. (EXEL) Earns Hold Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 11 at 3:12 PM |
| Exelixis' (EXEL) Buy Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - September 11 at 3:12 PM |
| Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors - Motley Fool
www.fool.com - September 10 at 10:50 PM |
| Analyzing Exelixis (EXEL) and Cascadian Therapeutics (CASC)
www.americanbankingnews.com - September 10 at 8:24 PM |
| Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
finance.yahoo.com - September 10 at 5:47 PM |
| 2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August - Motley Fool
www.fool.com - September 8 at 6:57 PM |
| 2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
www.fool.com - September 8 at 11:44 AM |
| Exelixis, Inc. (EXEL) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - September 7 at 10:44 PM |
| Exelixis Debuts New Mission-Driven Corporate Branding That ... - Business Wire (press release)
www.businesswire.com - September 7 at 6:35 PM |
| Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy
finance.yahoo.com - September 7 at 6:35 PM |
| Zacks: Brokerages Anticipate Exelixis, Inc. (EXEL) Will Announce Quarterly Sales of $103.83 Million
www.americanbankingnews.com - September 7 at 6:32 AM |
| Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress - Business Wire (press release)
www.businesswire.com - September 6 at 11:30 PM |
| Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress
finance.yahoo.com - September 6 at 6:29 PM |
| Brokerages Expect Exelixis, Inc. (EXEL) to Post $0.07 Earnings Per Share
www.americanbankingnews.com - September 5 at 10:26 AM |
| Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions? - Nasdaq
www.nasdaq.com - September 2 at 5:42 PM |
| Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - September 1 at 6:54 PM |
| Today's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation
finance.yahoo.com - August 31 at 6:23 PM |
| Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13 - Business Wire (press release)
www.businesswire.com - August 30 at 5:04 AM |
| Analyst Recommendations for Regeneron Pharmaceuticals in August
finance.yahoo.com - August 29 at 7:01 PM |
| Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
finance.yahoo.com - August 29 at 7:01 PM |
 | Stock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma, and Intra Cellular Therapies
www.bizjournals.com - August 28 at 6:17 PM |
 | Stock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma ...
www.prnewswire.com - August 28 at 6:17 PM |
| Can Buying Exelixis Stock Still Make You Rich?
www.fool.com - August 27 at 4:06 PM |
| Exelixis, Inc. (EXEL) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 26 at 8:44 AM |
| BidaskClub Upgrades Exelixis, Inc. (EXEL) to Strong-Buy
www.americanbankingnews.com - August 25 at 9:44 PM |
 | Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
globenewswire.com - August 23 at 12:05 AM |
| Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx - Nasdaq
www.nasdaq.com - August 18 at 12:48 AM |
 | Opdivo's Renal Failure Boosts Exelixis - Or Does It? - Seeking Alpha
seekingalpha.com - August 18 at 12:48 AM |
| Exelixis: Time To Reach The Top - Seeking Alpha
seekingalpha.com - August 18 at 12:48 AM |
| Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
finance.yahoo.com - August 17 at 7:45 PM |
 | Exelixis (EXEL) Submits sNDA for CABOMETYX for Treatment of Previously Untreated Advanced Kidney Cancer
www.streetinsider.com - August 16 at 11:39 PM |
Exelixis (EXEL) Chart for Thursday, September, 21, 2017
